|
|
Article: FDA approves atypical antipsychotic Geodon for acute bipolar mania.
- Article from:
- Life Science Weekly
- Article date:
- September 21, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 SEP 21 - (NewsRx.com & NewsRx.net) -- Pfizer, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Prompt and effective control of acute mania is an important goal as patients are at an increased risk for impulsive and dangerous behaviors, often requiring psychiatric hospitalization. Geodon was shown to rapidly improve acute manic symptoms and to sustain these improvements over a 3-week study period. Consistent with Geodon's overall clinical profile, no significant adverse effects on weight gain ...